Blis Technologies Limited — AGM Information 2025

Aug 21, 2025

==> picture [88 x 53] intentionally omitted <==

2025

==> picture [164 x 146] intentionally omitted <==

==> picture [243 x 243] intentionally omitted <==

ATTENDEES QUESTION & VOTING PROCESS

==> picture [510 x 123] intentionally omitted <==

----- Start of picture text -----

VOTING CARD
QUESTION BOX
----- End of picture text -----

2

MEETING AGENDA

BUSINESS OF THE MEETING

CHAIR’S ADDRESS

• Geoff Plunket

CHIEF EXECUTIVE OFFICER’S ADDRESS

• Scott Johnson

ORDINARY RESOLUTIONS

• That Amelia (Aimee) McCammon be re-elected as a Director

• That Dame Alison Stewart be re-elected as a Director

• Directors authorised to fix the auditors remuneration

SPECIAL RESOLUTION

• Amendment of the Constitution of the Company

OTHER BUSINESS

==> picture [480 x 540] intentionally omitted <==

3

BOARD OF DIRECTORS

==> picture [100 x 100] intentionally omitted <==

==> picture [100 x 100] intentionally omitted <==

GEOFFREY (GEOFF) PLUNKET

AMELIA (AIMEE) MCCAMMON

Chair, Independent non-executive Director

Independent non-executive Director

—

—

Member of Audit and Risk Committee and People and Performance Committee

Member of Audit and Risk Committee and People and Performance Committee

==> picture [100 x 100] intentionally omitted <==

==> picture [100 x 100] intentionally omitted <==

DAME ALISON STEWART

DR BARRY RICHARDSON

Independent non-executive Director

Independent non-executive Director

— —

Chair of Audit and Risk Committee

Chair of People and Performance Committee

==> picture [100 x 100] intentionally omitted <==

ANITA JOHANSEN

Non-executive Director

==> picture [206 x 371] intentionally omitted <==

==> picture [74 x 44] intentionally omitted <==

4

12.6M

10% on prior year

1.0M

26% on prior year

0.8M

30% on prior year

==> picture [74 x 44] intentionally omitted <==

CEO ADDRESS

SCOTT JOHNSON Chief Executive Officer

==> picture [74 x 44] intentionally omitted <==

6

LEADERSHIP TEAM

Left to right:

ASHLEIGH CHILDS People & Culture

MELISSA DRYSDALE Head of Quality

RICHARD WINGHAM Chief Financial Officer (CFO) SCOTT JOHNSON Chief Executive Officer (CEO) JENNIFER WALKER Chief Revenue Officer (CRO) DR JOHN HALE Chief Technology Officer (CTO)

==> picture [74 x 44] intentionally omitted <==

7

GLOBAL MARKET SNAPSHOT

PROBIOTIC DIETARY SUPPLEMENT MARKET

Market Size in USD Billion CAGR 11.96%

==> picture [196 x 169] intentionally omitted <==

----- Start of picture text -----

USD 22.01 B
USD 12.51 B
2025 2030
----- End of picture text -----

Source: Modor Intelligence 2025

==> picture [368 x 154] intentionally omitted <==

GLOBAL PROBIOTIC DIETARY SUPPLEMENTS MARKET SHARE BY REGION (2024)

==> picture [282 x 172] intentionally omitted <==

----- Start of picture text -----

10%
5.4% 22%
Europe
North America
Asia-Pacific
Rest of World
37.6% 25% Middle East & Africa
----- End of picture text -----

Source: Modor Intelligence 2025

==> picture [74 x 44] intentionally omitted <==

8

FY25 FINANCIAL PERFORMANCE

==> picture [368 x 154] intentionally omitted <==

==> picture [788 x 265] intentionally omitted <==

----- Start of picture text -----

REVENUE EBITDA NPAT
10% 26% 30%
on prior year on prior year on prior year
$m $m $m
14.0 1.2 1.5
12.6 1.0
1.0
12.0 11.5 0.8 1.0 0.8
10.2 0.8 0.6
10.0 0.6 0.5
8.0 0.4 -
0.2
6.0 - (0.5)
4.0 (0.2) (1.0)
(0.4)
2.0 (1.5)
(0.6) (1.4)
- (0.6)
(0.8) (2.0)
2023 2024 2025 2023 2024 2025 2023 2024 2025
----- End of picture text -----

==> picture [74 x 44] intentionally omitted <==

9

FY25 FINANCIAL PERFORMANCE

==> picture [368 x 154] intentionally omitted <==

==> picture [752 x 286] intentionally omitted <==

----- Start of picture text -----

CASH GENERATED REVENUE BY REGION REVENUE BY CHANNEL
FROM OPERATIONS
FY25 FY25
16%
New Zealand
70%%
36% EMEA 36%
on prior year B2B
Asia Pacific
B2C
$m 30% (excl. NZ) 64%
North America
2.0
1.8 18%
1.8
1.6
1.4
FY24 FY24
1.2 1.1
1.0 16%
New Zealand
0.8 29% 31%
EMEA
0.6 B2B
Asia Pacific
0.4 B2C
0.2 0.1 (excl. NZ) 69%
10%
- 44% North America
2023 2024 2025
----- End of picture text -----

CASH GENERATED FROM OPERATIONS

REVENUE BY CHANNEL

70%% on prior year

==> picture [74 x 44] intentionally omitted <==

10

REVENUE & MARKET PERFORMANCE B2B

==> picture [105 x 44] intentionally omitted <==

----- Start of picture text -----

8.1M
----- End of picture text -----

$ B2B

• Ingredient down slightly overall

• North America (+83%) and APAC (+53%) growth

• Royalty steady at $1.1m

• Private label up to $0.8m (+$0.5m)

B2B REVENUE (NZ$M)

==> picture [203 x 170] intentionally omitted <==

----- Start of picture text -----

$m
9
8.1
8.0
8
7 6.8
6
2023 2024 2025
----- End of picture text -----

==> picture [368 x 154] intentionally omitted <==

FY25 B2B REVENUE BY SALES CHANNEL (NZ$M)

==> picture [220 x 115] intentionally omitted <==

----- Start of picture text -----

14%
10% Ingredients: 6.2
Private label: 0.8
License fee
77%
and royalties: 1.1
----- End of picture text -----

==> picture [74 x 44] intentionally omitted <==

11

REVENUE & MARKET PERFORMANCE B2C

$ 4.5M B2C 29%

• 36% of total revenue (+from 31%)

• Amazon USA: $2m (+30%)

• BLIS Webstore: $0.6m (+19%)

• Strong growth from China CBEC

B2C REVENUE (NZ$M)

==> picture [18 x 11] intentionally omitted <==

----- Start of picture text -----

$m
----- End of picture text -----

==> picture [192 x 151] intentionally omitted <==

----- Start of picture text -----

5 4.5
4 3.5 3.5
3
2
1
0
2023 2024 2025
----- End of picture text -----

==> picture [368 x 154] intentionally omitted <==

FY25 B2C REVENUE BY SALES CHANNEL (NZ$M)

==> picture [225 x 115] intentionally omitted <==

----- Start of picture text -----

14%
30%
NZ wholesale: 1.4
CBEC: 0.5
Amazon USA: 2.0
44%
12%
BLIS webstore: 0.6
----- End of picture text -----

==> picture [74 x 44] intentionally omitted <==

12

IP AND MARKET RISKS

LEGAL AND SUPPLY AND MARKETING AGREEMENT

• Negotiations concluded on Bluestone Pharma GmbH (BSP) fermentation patent applications on July 2nd

==> picture [368 x 154] intentionally omitted <==

TARIFFS

• US: 15% tariff on finished goods (April 2025 price rise on Amazon)

• Joint ownership agreement reached

• Mutual release of claims by BLIS, BSP & Lactosan

• Renegotiated 5-year supply agreement extension with BSP

• Working together on joint business plan

==> picture [74 x 44] intentionally omitted <==

13

STRATEGIC FOCUS & EXECUTION

==> picture [203 x 183] intentionally omitted <==

==> picture [203 x 182] intentionally omitted <==

CONTINUED FOCUS ON CORE: K12™ & M18™

PROBI PARTNERSHIP IN US REMAINS CENTRAL

==> picture [368 x 154] intentionally omitted <==

==> picture [221 x 185] intentionally omitted <==

==> picture [203 x 183] intentionally omitted <==

FOCUSED PIPELINE OF CONSUMER INSIGHT DRIVEN R&D AND NPD PROJECTS

CHINA REGULATORY PROJECT NEAR COMPLETION

==> picture [74 x 44] intentionally omitted <==

14

FY26 STRATEGIC PLAN

==> picture [368 x 154] intentionally omitted <==

OUR PURPOSE

Being the best at developing probiotic solutions for the health and wellbeing of global consumers.

==> picture [128 x 108] intentionally omitted <==

----- Start of picture text -----

OUR IMPACT
OUR VISION
----- End of picture text -----

==> picture [128 x 103] intentionally omitted <==

----- Start of picture text -----

HOW WE DELIVER
----- End of picture text -----

==> picture [128 x 52] intentionally omitted <==

----- Start of picture text -----

OUR VALUES
----- End of picture text -----

PEOPLE PROFIT CUSTOMER Caring for our team Sustainable growth Building partnerships

We are acknowledged globally as the preferred partner and leader in oral probiotic innovation

TECHNOLOGY BUILDING BLOCKS COMMERCIAL ACTIVATION STRATEGIC DEMAND ALLIANCES R&D | NPD | Patents JBPs | Marketing | Go-to-Market Brand Owners | BLIS | Innovation Partners

PEOPLE STRATEGIC SUPPLY ALLIANCES MARKET ACCESS & SUPPORT QUALITY PROCESSES & SYSTEMS L&D | Performance Mgmt Fermentation | Manufacturing Science Center | Regulatory S&OP | Project Mgmt Account Mgmt | Comms Quality Testing Process Continuous Improvement

OUR MANA CUSTOMER FIRST MAKE IT HAPPEN ONE TEAM Inspires us Orients us Drives us Connects us

==> picture [74 x 44] intentionally omitted <==

15

ESG & CULTURE

B CORP CERTIFICATION PREPARATION

‘LEADING AT BLIS’ LEADERSHIP PROGRAMME

MYGREEN LAB: ZERO LTIs GREEN REFOR 6 YEARS CERTIFICATION

• To enhance shareholder value

• Formalises BLIS’ commitment to responsible, sustainable growth

• Requires minor constitutional change

==> picture [18 x 19] intentionally omitted <==

----- Start of picture text -----

16
----- End of picture text -----

==> picture [74 x 44] intentionally omitted <==

SUPPLY CHAIN

RAW INGREDIENT VOLUME AND PRICING PRESSURES One-off impact in Q1 and ongoing pressure

WORKING THROUGH AGREEMENT WITH ADDITIONAL FERMENTATION PARTNER TO ENSURE CUSTOMER DEMAND IS MET

==> picture [74 x 44] intentionally omitted <==

17

25 YEAR MILESTONE

FOUNDED IN 2000 ON PROF. JOHN TAGG’S RESEARCH

ONGOING SCIENTIFIC AND MENTORING ROLE AT BLIS

==> picture [345 x 291] intentionally omitted <==

GLOBAL RECOGNITION OF DISCOVERY AND CONTRIBUTION

18

CLOSING AND OUTLOOK

UNAUDITED RESULTS FOR THE QUARTER ENDING 30 JUNE 2025 (1Q26)

==> picture [368 x 154] intentionally omitted <==

OUTLOOK

• 1HY26 revenue of $7.5m, 25% increase on 1HY25

$ $ 3.5M ( 0.2M) REVENUE EBITDA

==> picture [362 x 151] intentionally omitted <==

• 1H26 positive EBITDA (inclusive of one-off costs)

• FY26 full year revenue growth of 10%–15%

==> picture [74 x 44] intentionally omitted <==

19

==> picture [56 x 56] intentionally omitted <==

WAIT FOR THE MICROPHONE

ATTENDEES QUESTION PROCESS

==> picture [510 x 49] intentionally omitted <==

----- Start of picture text -----

QUESTION BOX
----- End of picture text -----

==> picture [74 x 44] intentionally omitted <==

21

==> picture [56 x 56] intentionally omitted <==

WAIT FOR THE MICROPHONE

ATTENDEES VOTING PROCESS

==> picture [323 x 49] intentionally omitted <==

----- Start of picture text -----

VOTING CARD
----- End of picture text -----

==> picture [74 x 44] intentionally omitted <==

23

RESOLUTION 1 THAT AMELIA (AIMEE) MCCAMMON BE RE-ELECTED AS A DIRECTOR OF THE COMPANY.

==> picture [56 x 57] intentionally omitted <==

WAIT FOR THE MICROPHONE

State your name and whether you are a shareholder or proxy holder.

==> picture [303 x 484] intentionally omitted <==

24

RESOLUTION 2 THAT DAME ALISON STEWART BE RE-ELECTED AS A DIRECTOR OF THE COMPANY.

==> picture [56 x 57] intentionally omitted <==

WAIT FOR THE MICROPHONE

State your name and whether you are a shareholder or proxy holder.

==> picture [303 x 484] intentionally omitted <==

25

RESOLUTION 3 THAT THE DIRECTORS BE AUTHORISED TO FIX THE REMUNERATION OF THE AUDITORS FOR THE ENSUING YEAR.

==> picture [56 x 57] intentionally omitted <==

WAIT FOR THE MICROPHONE

State your name and whether you are a shareholder or proxy holder.

==> picture [74 x 44] intentionally omitted <==

26

RESOLUTION (SPECIAL) 4 AMENDMENT OF THE CONSTITUTION OF THE COMPANY.

==> picture [56 x 57] intentionally omitted <==

WAIT FOR THE MICROPHONE

State your name and whether you are a shareholder or proxy holder.

==> picture [74 x 44] intentionally omitted <==

27

GENERAL BUSINESS

DISCLAIMER

INFORMATION

The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of BLIS Technologies Limited (“Company” or “BLIS”). The information in this presentation is of a general nature and does not purport to be complete. This presentation should be read in conjunction with the Company’s other periodic and continuous disclosure announcements, which are available at nzx.com.

NOT FINANCIAL PRODUCT ADVICE

This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire BLIS securities, and has been prepared without taking into account the objectives, financial situation or needs of individuals. The Company, its directors and employees do not give or make any recommendation or opinion in relation to acquiring or disposing of shares. In making an investment decision, investors must rely on their own examination of the Company, including the merits and risks involved. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any acquisition of securities.

==> picture [353 x 150] intentionally omitted <==

==> picture [331 x 146] intentionally omitted <==

FUTURE PERFORMANCE

This presentation may contain certain ‘forward-looking statements’, for example statements concerning the development and commercialisation of new products, regulatory approvals, customer adoption and results of future clinical studies. Forward-looking statements can generally be identified by the use of forward-looking words such as, ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘could’, ‘may’, ‘predict’, ‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’ and other similar expressions. The forward-looking statements contained in this presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of the Company and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not materially differ from these forwardlooking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forwardlooking statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation (including the NZX Main Board Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

NO REPRESENTATION

This presentation may contain information from third-parties believed to be reliable, however, no representations or warranties are made

==> picture [74 x 44] intentionally omitted <==

29

THANK YOU

==> picture [74 x 45] intentionally omitted <==